Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis | Adolescent Medicine | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
Degenhardt  L, Charlson  F, Ferrari  A,  et al; GBD 2016 Alcohol and Drug Use Collaborators.  The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.   Lancet Psychiatry. 2018;5(12):987-1012. doi:10.1016/S2215-0366(18)30337-7 PubMedGoogle Scholar
2.
Crean  RD, Tapert  SF, Minassian  A, Macdonald  K, Crane  NA, Mason  BJ.  Effects of chronic, heavy cannabis use on executive functions.   J Addict Med. 2011;5(1):9-15. doi:10.1097/ADM.0b013e31820cdd57 PubMedGoogle Scholar
3.
Volkow  ND, Baler  RD, Compton  WM, Weiss  SRB.  Adverse health effects of marijuana use.   N Engl J Med. 2014;370(23):2219-2227. doi:10.1056/NEJMra1402309 PubMedGoogle Scholar
4.
Carvalho  AF, Stubbs  B, Vancampfort  D,  et al.  Cannabis use and suicide attempts among 86,254 adolescents aged 12-15 years from 21 low- and middle-income countries.   Eur Psychiatry. 2019;56:8-13. doi:10.1016/j.eurpsy.2018.10.006 PubMedGoogle Scholar
5.
Budney  AJ, Hughes  JR.  The cannabis withdrawal syndrome.   Curr Opin Psychiatry. 2006;19(3):233-238. doi:10.1097/01.yco.0000218592.00689.e5 PubMedGoogle Scholar
6.
Budney  AJ, Novy  PL, Hughes  JR.  Marijuana withdrawal among adults seeking treatment for marijuana dependence.   Addiction. 1999;94(9):1311-1322. doi:10.1046/j.1360-0443.1999.94913114.x PubMedGoogle Scholar
7.
Budney  AJ, Moore  BA, Vandrey  RG, Hughes  JR.  The time course and significance of cannabis withdrawal.   J Abnorm Psychol. 2003;112(3):393-402. doi:10.1037/0021-843X.112.3.393 PubMedGoogle Scholar
8.
Budney  AJ, Hughes  JR, Moore  BA, Vandrey  R.  Review of the validity and significance of cannabis withdrawal syndrome.   Am J Psychiatry. 2004;161(11):1967-1977. doi:10.1176/appi.ajp.161.11.1967 PubMedGoogle Scholar
9.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association Publishing; 2013.
10.
Hasin  DS.  US epidemiology of cannabis use and associated problems.   Neuropsychopharmacology. 2018;43(1):195-212. doi:10.1038/npp.2017.198 PubMedGoogle Scholar
11.
Anthony  JC, Lopez-Quintero  C, Alshaarawy  O.  Cannabis epidemiology: a selective review.   Curr Pharm Des. 2017;22(42):6340-6352. doi:10.2174/1381612822666160813214023 PubMedGoogle Scholar
12.
Bahji  A, Mazhar  MN.  Treatment of cannabis dependence with synthetic cannabinoids: a systematic review.   Can J Addict. 2016;7(4):8-13.Google Scholar
13.
National Institute for Health Research. PROSPERO International prospective register of systematic reviews. 2019. Accessed November 24, 2019. https://www.crd.york.ac.uk/PROSPERO/
14.
Liberati  A, Altman  DG, Tetzlaff  J,  et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.   PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100 PubMedGoogle Scholar
15.
Roy Rosenzweig Center for History and New Media. Zotero; 2018. Accessed March 9, 2020. https://rrchnm.org/zotero/
16.
Covidence: better systematic review management.  Veritas Health Innovation. Accessed March 9, 2020. https://www.covidence.org/home
17.
Cottler  LB, Schuckit  MA, Helzer  JE,  et al.  The DSM-IV field trial for substance use disorders: major results.   Drug Alcohol Depend. 1995;38(1):59-69. doi:10.1016/0376-8716(94)01091-X PubMedGoogle Scholar
18.
Wiesbeck  GA, Schuckit  MA, Kalmijn  JA, Tipp  JE, Bucholz  KK, Smith  TL.  An evaluation of the history of a marijuana withdrawal syndrome in a large population.   Addiction. 1996;91(10):1469-1478. doi:10.1111/j.1360-0443.1996.tb02251.x PubMedGoogle Scholar
19.
Budney  AJ, Radonovich  KJ, Higgins  ST, Wong  CJ.  Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers.   Exp Clin Psychopharmacol. 1998;6(4):419-426. doi:10.1037/1064-1297.6.4.419 PubMedGoogle Scholar
20.
Crowley  TJ, Macdonald  MJ, Whitmore  EA, Mikulich  SK.  Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders.   Drug Alcohol Depend. 1998;50(1):27-37. doi:10.1016/S0376-8716(98)00003-9 PubMedGoogle Scholar
21.
Swift  W, Hall  W, Didcott  P, Reilly  D.  Patterns and correlates of cannabis dependence among long-term users in an Australian rural area.   Addiction. 1998;93(8):1149-1160. doi:10.1046/j.1360-0443.1998.93811493.x PubMedGoogle Scholar
22.
Schuckit  MA, Daeppen  J-B, Danko  GP,  et al.  Clinical implications for four drugs of the DSM-IV distinction between substance dependence with and without a physiological component.   Am J Psychiatry. 1999;156(1):41-49. doi:10.1176/ajp.156.1.41 PubMedGoogle Scholar
23.
Kouri  EM, Pope  HG  Jr.  Abstinence symptoms during withdrawal from chronic marijuana use.   Exp Clin Psychopharmacol. 2000;8(4):483-492. doi:10.1037/1064-1297.8.4.483 PubMedGoogle Scholar
24.
Swift  W, Hall  W, Copeland  J.  One year follow-up of cannabis dependence among long-term users in Sydney, Australia.   Drug Alcohol Depend. 2000;59(3):309-318. doi:10.1016/S0376-8716(99)00131-3 PubMedGoogle Scholar
25.
Swift  W, Hall  W, Teesson  M.  Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing.   Drug Alcohol Depend. 2001;63(2):147-153. doi:10.1016/S0376-8716(00)00197-6 PubMedGoogle Scholar
26.
Stephens  RS, Babor  TF, Kadden  R, Miller  M; Marijuana Treatment Project Research Group.  The Marijuana Treatment Project: rationale, design and participant characteristics.   Addiction. 2002;97(s1)(suppl 1):109-124. doi:10.1046/j.1360-0443.97.s01.6.x PubMedGoogle Scholar
27.
Vandrey  R, Budney  AJ, Kamon  JL, Stanger  C.  Cannabis withdrawal in adolescent treatment seekers.   Drug Alcohol Depend. 2005;78(2):205-210. doi:10.1016/j.drugalcdep.2004.11.001 PubMedGoogle Scholar
28.
Copersino  ML, Boyd  SJ, Tashkin  DP,  et al.  Cannabis withdrawal among non–treatment-seeking adult cannabis users.   Am J Addict. 2006;15(1):8-14. doi:10.1080/10550490500418997 PubMedGoogle Scholar
29.
Levin  FR, Brooks  DJ, Bisaga  A,  et al.  Severity of dependence and motivation for treatment: comparison of marijuana- and cocaine-dependent treatment seekers.   J Addict Dis. 2006;25(1):33-41. doi:10.1300/J069v25n01_06 PubMedGoogle Scholar
30.
Nocon  A, Wittchen  HU, Pfister  H, Zimmermann  P, Lieb  R.  Dependence symptoms in young cannabis users? a prospective epidemiological study.   J Psychiatr Res. 2006;40(5):394-403. doi:10.1016/j.jpsychires.2005.07.011 PubMedGoogle Scholar
31.
Lukasiewicz  M, Falissard  B, Michel  L, Neveu  X, Reynaud  M, Gasquet  I.  Prevalence and factors associated with alcohol and drug-related disorders in prison: a French national study.   Subst Abuse Treat Prev Policy. 2007;2:1. doi:10.1186/1747-597X-2-1 PubMedGoogle Scholar
32.
Agrawal  A, Pergadia  ML, Lynskey  MT.  Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions?   Am J Addict. 2008;17(3):199-208. doi:10.1080/10550490802019519 PubMedGoogle Scholar
33.
Chung  T, Martin  CS, Cornelius  JR, Clark  DB.  Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents.   Addiction. 2008;103(5):787-799. doi:10.1111/j.1360-0443.2008.02158.x PubMedGoogle Scholar
34.
Cornelius  JR, Chung  T, Martin  C, Wood  DS, Clark  DB.  Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.   Addict Behav. 2008;33(11):1500-1505. doi:10.1016/j.addbeh.2008.02.001 PubMedGoogle Scholar
35.
Hasin  DS, Keyes  KM, Alderson  D, Wang  S, Aharonovich  E, Grant  BF.  Cannabis withdrawal in the United States: results from NESARC.   J Clin Psychiatry. 2008;69(9):1354-1363. doi:10.4088/JCP.v69n0902 PubMedGoogle Scholar
36.
Jungerman  FS, Laranjeira  R.  Characteristics of cannabis users seeking treatment in São Paulo, Brazil.   Rev Panam Salud Publica. 2008;23(6):384-393. doi:10.1590/S1020-49892008000600003 PubMedGoogle Scholar
37.
Milin  R, Manion  I, Dare  G, Walker  S.  Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study.   J Am Acad Child Adolesc Psychiatry. 2008;47(2):174-179. doi:10.1097/chi.0b013e31815cdd73 PubMedGoogle Scholar
38.
Vandrey  RG, Budney  AJ, Hughes  JR, Liguori  A.  A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances.   Drug Alcohol Depend. 2008;92(1-3):48-54. doi:10.1016/j.drugalcdep.2007.06.010 PubMedGoogle Scholar
39.
Mennes  CE, Ben Abdallah  A, Cottler  LB.  The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: multisite study of differences between general population and treatment groups.   Addict Behav. 2009;34(2):223-226. doi:10.1016/j.addbeh.2008.10.003 PubMedGoogle Scholar
40.
Ehlers  CL, Gizer  IR, Vieten  C,  et al.  Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability.   Addict Behav. 2010;35(2):102-110. doi:10.1016/j.addbeh.2009.09.009 PubMedGoogle Scholar
41.
Levin  KH, Copersino  ML, Heishman  SJ,  et al.  Cannabis withdrawal symptoms in non–treatment-seeking adult cannabis smokers.   Drug Alcohol Depend. 2010;111(1-2):120-127. doi:10.1016/j.drugalcdep.2010.04.010 PubMedGoogle Scholar
42.
Preuss  UW, Watzke  AB, Zimmermann  J, Wong  JW, Schmidt  CO.  Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients.   Drug Alcohol Depend. 2010;106(2-3):133-141. doi:10.1016/j.drugalcdep.2009.08.008 PubMedGoogle Scholar
43.
Vorspan  F, Guillem  E, Bloch  V,  et al.  Self-reported sleep disturbances during cannabis withdrawal in cannabis-dependent outpatients with and without opioid dependence.   Sleep Med. 2010;11(5):499-500. doi:10.1016/j.sleep.2009.12.001 PubMedGoogle Scholar
44.
Dervaux  A, Krebs  MO, Laqueille  X.  Anxiety and depressive symptoms or disorders in patients with cannabis dependence without major psychiatric disorders.   Eur Neuropsychopharmacol. 2011;21(suppl 3):S578-S579. doi:10.1016/S0924-977X(11)70946-4 Google Scholar
45.
Gorelick  DA, Levin  KH, Copersino  ML,  et al.  Diagnostic criteria for cannabis withdrawal syndrome.   Drug Alcohol Depend. 2012;123(1-3):141-147. doi:10.1016/j.drugalcdep.2011.11.007 PubMedGoogle Scholar
46.
Boggs  DL, Kelly  DL, Liu  F,  et al.  Cannabis withdrawal in chronic cannabis users with schizophrenia.   J Psychiatr Res. 2013;47(2):240-245. doi:10.1016/j.jpsychires.2012.10.010 PubMedGoogle Scholar
47.
Smith  PH, Homish  GG, Leonard  KE, Collins  RL.  Marijuana withdrawal and aggression among a representative sample of US marijuana users.   Drug Alcohol Depend. 2013;132(1-2):63-68. doi:10.1016/j.drugalcdep.2013.01.002 PubMedGoogle Scholar
48.
Verweij  KJ, Agrawal  A, Nat  NO,  et al.  A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5.   Psychol Med. 2013;43(8):1713-1722. doi:10.1017/S0033291712002735 PubMedGoogle Scholar
49.
Bonnet  U, Specka  M, Stratmann  U, Ochwadt  R, Scherbaum  N.  Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.   Drug Alcohol Depend. 2014;143:189-197. doi:10.1016/j.drugalcdep.2014.07.027PubMedGoogle Scholar
50.
Greene  MC, Kelly  JF.  The prevalence of cannabis withdrawal and its influence on adolescents’ treatment response and outcomes: a 12-month prospective investigation.   J Addict Med. 2014;8(5):359-367. doi:10.1097/ADM.0000000000000064 PubMedGoogle Scholar
51.
Lee  D, Schroeder  JR, Karschner  EL,  et al.  Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment.   Am J Addict. 2014;23(3):234-242. doi:10.1111/j.1521-0391.2014.12088.x PubMedGoogle Scholar
52.
Delforterie  M, Creemers  H, Agrawal  A,  et al.  Functioning of cannabis abuse and dependence criteria across two different countries: the United States and the Netherlands.   Subst Use Misuse. 2015;50(2):242-250. doi:10.3109/10826084.2014.952445 PubMedGoogle Scholar
53.
Herrmann  ES, Weerts  EM, Vandrey  R.  Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.   Exp Clin Psychopharmacol. 2015;23(6):415-421. doi:10.1037/pha0000053 PubMedGoogle Scholar
54.
Macfarlane  V, Christie  G.  Synthetic cannabinoid withdrawal: a new demand on detoxification services.   Drug Alcohol Rev. 2015;34(2):147-153. doi:10.1111/dar.12225 PubMedGoogle Scholar
55.
Soenksen  S, Stein  LAR, Brown  JD, Stengel  JR, Rossi  JS, Lebeau  R.  Cannabis withdrawal among detained adolescents: exploring the impact of nicotine and race.   J Child Adolesc Subst Abuse. 2015;24(2):119-124. doi:10.1080/1067828X.2013.770379 PubMedGoogle Scholar
56.
Davis  JP, Smith  DC, Morphew  JW, Lei  X, Zhang  S.  Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment: a prospective study.   J Drug Issues. 2016;46(1):64-83. doi:10.1177/0022042615616431 PubMedGoogle Scholar
57.
Sherman  BJ, McRae-Clark  AL, Baker  NL,  et al.  Gender differences among treatment-seeking adults with cannabis use disorder: clinical profiles of women and men enrolled in the Achieving Cannabis Cessation–Evaluating N-Acetylcysteine Treatment (ACCENT) study.   Am J Addict. 2017;26(2):136-144. doi:10.1111/ajad.12503 PubMedGoogle Scholar
58.
Chauchard  E, Hartwell  KJ, McRae-Clark  AL, Sherman  BJ, Gorelick  DA.  Cannabis withdrawal in adults with attention-deficit/hyperactivity disorder.   Prim Care Companion CNS Disord. 2018;20(1):17m02203. doi:10.4088/PCC.17m02203 PubMedGoogle Scholar
59.
Livne  O, Shmulewitz  D, Lev-Ran  S, Hasin  DS.  DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in US adults.   Drug Alcohol Depend. 2019;195:170-177. doi:10.1016/j.drugalcdep.2018.09.005 PubMedGoogle Scholar
60.
Perron  BE, Holt  KR, Yeagley  E, Ilgen  M.  Mental health functioning and severity of cannabis withdrawal among medical cannabis users with chronic pain.   Drug Alcohol Depend. 2019;194:401-409. doi:10.1016/j.drugalcdep.2018.09.029 PubMedGoogle Scholar
61.
Bahji  A, Mazhar  MN, Hudson  CC, Nadkarni  P, MacNeil  BA, Hawken  E.  Prevalence of substance use disorder comorbidity among individuals with eating disorders: a systematic review and meta-analysis.   Psychiatry Res. 2019;273:58-66. doi:10.1016/j.psychres.2019.01.007 PubMedGoogle Scholar
62.
Bahji  A, Hawken  ER, Sepehry  AA, Cabrera  CA, Vazquez  G.  ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression.   Acta Psychiatr Scand. 2019;139(3):214-226. doi:10.1111/acps.12994PubMedGoogle Scholar
63.
von Elm  E, Altman  DG, Egger  M, Pocock  SJ, Gøtzsche  PC, Vandenbroucke  JP; STROBE Initiative.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.   BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD PubMedGoogle Scholar
64.
Degenhardt  L, Ferrari  AJ, Calabria  B,  et al.  The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study.   PLoS One. 2013;8(10):e76635. doi:10.1371/journal.pone.0076635 PubMedGoogle Scholar
65.
Degenhardt  L, Coffey  C, Romaniuk  H,  et al.  The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood.   Addiction. 2013;108(1):124-133. doi:10.1111/j.1360-0443.2012.04015.x PubMedGoogle Scholar
66.
Wells  G, Shea  B, O’Connell  D,  et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed May 23, 2019. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
67.
Viechtbauer  W.  Conducting meta-analyses in R with the metafor package.   J Stat Softw. 2010;36(3):1-48. doi:10.18637/jss.v036.i03PubMedGoogle Scholar
68.
Miller  JJ.  The inverse of the Freeman–Tukey double arcsine transformation.   Am Stat. 1978;32(4):138. doi:10.1080/00031305.1978.10479283Google Scholar
69.
Higgins  JPT, Thompson  SG.  Quantifying heterogeneity in a meta-analysis.   Stat Med. 2002;21(11):1539-1558. doi:10.1002/sim.1186 PubMedGoogle Scholar
70.
Willis  BH, Riley  RD.  Measuring the statistical validity of summary meta-analysis and meta-regression results for use in clinical practice.   Stat Med. 2017;36(21):3283-3301. doi:10.1002/sim.7372 PubMedGoogle Scholar
71.
Egger  M, Davey Smith  G, Schneider  M, Minder  C.  Bias in meta-analysis detected by a simple, graphical test.   BMJ. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629 PubMedGoogle Scholar
72.
Duval  S, Tweedie  R.  Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.   Biometrics. 2000;56(2):455-463. doi:10.1111/j.0006-341X.2000.00455.x PubMedGoogle Scholar
73.
Begg  CB, Mazumdar  M.  Operating characteristics of a rank correlation test for publication bias.   Biometrics. 1994;50(4):1088-1101. doi:10.2307/2533446 PubMedGoogle Scholar
74.
Allsop  DJ, Norberg  MM, Copeland  J, Fu  S, Budney  AJ.  The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.   Drug Alcohol Depend. 2011;119(1-2):123-129. doi:10.1016/j.drugalcdep.2011.06.003 PubMedGoogle Scholar
75.
Sobell  LC, Sobell  MB. Timeline follow-back. In: Litten  RZ, Allen  JP, eds.  Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Humana Press; 1992:41-72, . doi:10.1007/978-1-4612-0357-5_3
76.
First  MB. Structured Clinical Interview for the DSM (SCID). In:  The Encyclopedia of Clinical Psychology. American Cancer Society; 2015:1-6. doi:10.1002/9781118625392.wbecp351
77.
American Psychiatric Association.  DSM-V: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596
78.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems; 11th Revision, 2018 version. Accessed November 24, 2019. https://icd.who.int/browse11/l-m/en
79.
Sheehan  DV, Lecrubier  Y, Sheehan  KH,  et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.   J Clin Psychiatry. 1998;59(suppl 20):22-33.PubMedGoogle Scholar
80.
Katz  G, Lobel  T, Tetelbaum  A, Raskin  S.  Cannabis withdrawal—a new diagnostic category in DSM-5.   Isr J Psychiatry Relat Sci. 2014;51(4):270-275.PubMedGoogle Scholar
81.
Bonn-Miller  MO, Boden  MT, Bucossi  MM, Babson  KA.  Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.   Am J Drug Alcohol Abuse. 2014;40(1):23-30. doi:10.3109/00952990.2013.821477 PubMedGoogle Scholar
82.
Swift  W, Gates  P, Dillon  P.  Survey of Australians using cannabis for medical purposes.   Harm Reduct J. 2005;2(1):18. doi:10.1186/1477-7517-2-18 PubMedGoogle Scholar
83.
Walsh  Z, Gonzalez  R, Crosby  K, S Thiessen  M, Carroll  C, Bonn-Miller  MO.  Medical cannabis and mental health: a guided systematic review.   Clin Psychol Rev. 2017;51:15-29. doi:10.1016/j.cpr.2016.10.002 PubMedGoogle Scholar
84.
Allsop  DJ, Copeland  J, Norberg  MM,  et al.  Quantifying the clinical significance of cannabis withdrawal.   PLoS One. 2012;7(9):e44864. doi:10.1371/journal.pone.0044864 PubMedGoogle Scholar
85.
Budney  AJ, Vandrey  RG, Hughes  JR, Thostenson  JD, Bursac  Z.  Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse.   J Subst Abuse Treat. 2008;35(4):362-368. doi:10.1016/j.jsat.2008.01.002 PubMedGoogle Scholar
86.
Agrawal  A, Lynskey  MT, Madden  PAF, Bucholz  KK, Heath  AC.  A latent class analysis of illicit drug abuse/dependence: results from the National Epidemiological Survey on Alcohol and Related Conditions.   Addiction. 2007;102(1):94-104. doi:10.1111/j.1360-0443.2006.01630.x PubMedGoogle Scholar
87.
Budney  AJ, Roffman  R, Stephens  RS, Walker  D.  Marijuana dependence and its treatment.   Addict Sci Clin Pract. 2007;4(1):4-16. doi:10.1151/ASCP07414 PubMedGoogle Scholar
88.
Haney  M, Hart  CL, Vosburg  SK,  et al.  Marijuana withdrawal in humans: effects of oral THC or divalproex.   Neuropsychopharmacology. 2004;29(1):158-170. doi:10.1038/sj.npp.1300310 PubMedGoogle Scholar
89.
Lichtman  AH, Martin  BR.  Marijuana withdrawal syndrome in the animal model.   J Clin Pharmacol. 2002;42(S1):20S-27S. doi:10.1002/j.1552-4604.2002.tb05999.x PubMedGoogle Scholar
90.
González  S, Cebeira  M, Fernández-Ruiz  J.  Cannabinoid tolerance and dependence: a review of studies in laboratory animals.   Pharmacol Biochem Behav. 2005;81(2):300-318. doi:10.1016/j.pbb.2005.01.028 PubMedGoogle Scholar
91.
Hirvonen  J, Goodwin  RS, Li  C-T,  et al.  Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.   Mol Psychiatry. 2012;17(6):642-649. doi:10.1038/mp.2011.82 PubMedGoogle Scholar
92.
Sim-Selley  LJ.  Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.   Crit Rev Neurobiol. 2003;15(2):91-119. doi:10.1615/CritRevNeurobiol.v15.i2.10 PubMedGoogle Scholar
93.
Sim-Selley  LJ, Schechter  NS, Rorrer  WK,  et al.  Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration.   Mol Pharmacol. 2006;70(3):986-996. doi:10.1124/mol.105.019612 PubMedGoogle Scholar
94.
Schlosburg  JE, Carlson  BLA, Ramesh  D,  et al.  Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.   AAPS J. 2009;11(2):342-352. doi:10.1208/s12248-009-9110-7 PubMedGoogle Scholar
95.
Paulus  DJ, Manning  K, Hogan  JBD, Zvolensky  MJ.  The role of anxiety sensitivity in the relation between anxious arousal and cannabis and alcohol use problems among low-income inner city racial/ethnic minorities.   J Anxiety Disord. 2017;48:87-94. doi:10.1016/j.janxdis.2016.07.011 PubMedGoogle Scholar
96.
Crippa  JA, Zuardi  AW, Martín-Santos  R,  et al.  Cannabis and anxiety: a critical review of the evidence.   Hum Psychopharmacol. 2009;24(7):515-523. doi:10.1002/hup.1048 PubMedGoogle Scholar
97.
Arias  F, Szerman  N, Vega  P,  et al.  Abuse or dependence on cannabis and other psychiatric disorders: Madrid study on dual pathology prevalence.   Actas Esp Psiquiatr. 2013;41(2):122-129.PubMedGoogle Scholar
98.
Koola  MM, Boggs  DL, Kelly  DL,  et al.  Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia.   Psychiatry Res. 2013;209(3):273-278. doi:10.1016/j.psychres.2013.07.044 PubMedGoogle Scholar
99.
Koola  MM, Kelly  DL, McMahon  RP, Boggs  DL, Liu  F, Gorelick  DA.  Psychoactive substance use by adults with schizophrenia before and during cannabis withdrawal.   Prim Care Companion CNS Disord. 2016;18(5). doi:10.4088/PCC.16l01959 PubMedGoogle Scholar
100.
Hanna  RC, Perez  JM, Ghose  S.  Cannabis and development of dual diagnoses: a literature review.   Am J Drug Alcohol Abuse. 2017;43(4):442-455. doi:10.1080/00952990.2016.1213273 PubMedGoogle Scholar
101.
MacDonald  K, Pappas  K.  Why not pot? a review of the brain-based risks of cannabis   Innov Clin Neurosci. 2016;13(3-4):13-22.PubMedGoogle Scholar
102.
Lev-Ran  S, Le Foll  B, McKenzie  K, George  TP, Rehm  J.  Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates.   Psychiatry Res. 2013;209(3):459-465. doi:10.1016/j.psychres.2012.12.014 PubMedGoogle Scholar
103.
Gage  SH.  Cannabis and psychosis: triangulating the evidence.   Lancet Psychiatry. 2019;6(5):364-365. doi:10.1016/S2215-0366(19)30086-0 PubMedGoogle Scholar
104.
Pacek  LR, Martins  SS, Crum  RM.  The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample.   J Affect Disord. 2013;148(2-3):188-195. doi:10.1016/j.jad.2012.11.059 PubMedGoogle Scholar
105.
Womack  SR, Shaw  DS, Weaver  CM, Forbes  EE.  Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men.   J Stud Alcohol Drugs. 2016;77(2):287-297. doi:10.15288/jsad.2016.77.287 PubMedGoogle Scholar
106.
Khantzian  EJ.  The self-medication hypothesis of substance use disorders: a reconsideration and recent applications.   Harv Rev Psychiatry. 1997;4(5):231-244. doi:10.3109/10673229709030550 PubMedGoogle Scholar
107.
Haney  M, Evins  AE.  Does cannabis cause, exacerbate or ameliorate psychiatric disorders? an oversimplified debate discussed.   Neuropsychopharmacology. 2016;41(2):393-401. doi:10.1038/npp.2015.251 PubMedGoogle Scholar
108.
Hodgins  DC, Stea  JN.  Psychometric evaluation of a lifetime version of the marijuana problems scale.   Addict Behav Rep. 2018;8:21-24. doi:10.1016/j.abrep.2018.05.001 PubMedGoogle Scholar
109.
Marshall  K, Gowing  L, Ali  R, Le Foll  B.  Pharmacotherapies for cannabis dependence.   Cochrane Database Syst Rev. 2014;(12):CD008940. doi:10.1002/14651858.CD008940.pub2PubMedGoogle Scholar
110.
McLellan  AT, Kushner  H, Metzger  D,  et al.  The fifth edition of the Addiction Severity Index.   J Subst Abuse Treat. 1992;9(3):199-213. doi:10.1016/0740-5472(92)90062-SPubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Substance Use and Addiction
    April 9, 2020

    Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis

    Author Affiliations
    • 1Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada
    • 2Department of Psychiatry, Queen’s University, Kingston, Ontario, Canada
    • 3Queen’s University School of Kinesiology and Health Studies, Kingston, Ontario, Canada
    • 4Cumming School of Medicine, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
    JAMA Netw Open. 2020;3(4):e202370. doi:10.1001/jamanetworkopen.2020.2370
    Key Points español 中文 (chinese)

    Questions  What is the prevalence of cannabis withdrawal syndrome among individuals with regular or dependent use of cannabis, and which factors are associated with cannabis withdrawal syndrome?

    Findings  In this meta-analysis of observational studies including 23 518 participants, the prevalence of cannabis withdrawal syndrome was found to be 47%. Factors that were associated with higher cannabis withdrawal syndrome were clinical settings (particularly inpatient and outpatient vs population settings), concurrent tobacco or other substance use, and daily cannabis use.

    Meaning  Cannabis withdrawal syndrome appears to be common among regular users of cannabis, particularly those in outpatient and inpatient settings and individuals with substance use disorders; clinicians should be aware of the high prevalence of cannabis withdrawal syndrome to counsel patients and support individuals who are reducing their use of cannabis.

    Abstract

    Importance  Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use disorder—commonly occurs on cessation of heavy and prolonged cannabis use. To date, the prevalence of CWS syndrome has not been well described, nor have the factors potentially associated with CWS.

    Objectives  To estimate the prevalence of CWS among individuals with regular or dependent use of cannabinoids and identify factors associated with CWS.

    Data Sources  A search of literature from database inception to June 19, 2019, was performed using MEDLINE, Embase, PsycINFO, Web of Science, the Cumulative Index to Nursing and Allied Health Literature, ProQuest, Allied and Complementary Medicine, and Psychiatry online, supplemented by manual searches of reference lists of included articles.

    Study Selection  Articles were included if they (1) were published in English, (2) reported on individuals with regular use of cannabinoids or cannabis use disorder as a primary study group, (3) reported on the prevalence of CWS or CWS symptoms using a validated instrument, (4) reported the prevalence of CWS, and (5) used an observational study design (eg, cohort or cross-sectional).

    Data Extraction and Synthesis  All abstracts, full-text articles, and other sources were reviewed, with data extracted in duplicate. Cannabis withdrawal syndrome prevalence was estimated using a random-effects meta-analysis model, alongside stratification and meta-regression to characterize heterogeneity.

    Main Outcomes and Measures  Cannabis withdrawal syndrome prevalence was reported as a percentage with 95% CIs.

    Results  Of 3848 unique abstracts, 86 were selected for full-text review, and 47 studies, representing 23 518 participants, met all inclusion criteria. Of 23 518 participants included in the analysis, 16 839 were white (72%) and 14 387 were men (69%); median (SD) age was 29.9 (9.0) years. The overall pooled prevalence of CWS was 47% (6469 of 23 518) (95% CI, 41%-52%), with significant heterogeneity between estimates (I2 = 99.2%). When stratified by source, the prevalence of CWS was 17% (95% CI, 13%-21%) in population-based samples, 54% in outpatient samples (95% CI, 48%-59%), and 87% in inpatient samples (95% CI, 79%-94%), which were significantly different (P < .001). Concurrent cannabis (β = 0.005, P < .001), tobacco (β = 0.002, P = .02), and other substance use disorders (β = 0.003, P = .05) were associated with a higher CWS prevalence, as was daily cannabis use (β = 0.004, P < .001).

    Conclusions and Relevance  These findings suggest that cannabis withdrawal syndrome appears to be prevalent among regular users of cannabis. Clinicians should be aware of the prevalence of CWS in order to counsel patients and support individuals who are reducing their use of cannabis.

    ×